Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

CzechiaBack to Czechia

Clinical trials in Novy Jicin – page 7

544 clinical trials in Novy Jicin, Czechia across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

CzechiaOur site in CzechiaKlinickeTesty.cz(opens in a new tab)
Novy Jicin at a glance
544
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

544 trials in Novy Jicin

Open in trial search

Fallopian tube cancer+2

Recruiting

Phase 3 Study of LY4170156 (Sofetabart Mipitecan) with drug combination in platinum‑resistant and platinum‑sensitive ovarian cancer patients

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Eli Lilly & Co.

Renal cell carcinoma

Recruiting

Belzutifan and Zanzalintinib in Adults with Advanced Renal Cell Carcinoma After PD-1/L1 and VEGF-TKI Therapy

Registered drug
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Belzutifan
  • Sponsor:Merck Sharp & Dohme LLC

Kidney transplant rejection

Recruiting

Frexalimab versus Tacrolimus for Prevention of Kidney Transplant Rejection in Adult Kidney Transplant Recipients

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Frexalimab
  • Sponsor:Sanofi-Aventis Recherche & Developpement

Ovarian cancer

Recruiting

A study of sacituzumab tirumotecan and bevacizumab in patients with newly diagnosed advanced ovarian cancer following first-line platinum-based chemotherapy

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Bevacizumab
  • Sponsor:Merck Sharp & Dohme LLC

Chronic lymphocytic leukaemia recurrent+1

Recruiting

A study of acalabrutinib and venetoclax for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma who have relapsed after initial treatment

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:AstraZeneca AB

Obesity+1

Recruiting

A study of eloralintide in adults with persistent obesity or overweight who are currently treated with a weekly incretin medication

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

B-cell small lymphocytic lymphoma

Recruiting

A study comparing BGB-11417 and zanubrutinib with venetoclax and acalabrutinib for patients with previously untreated chronic lymphocytic leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Acalabrutinib
  • Sponsor:BeOne Medicines I GmbH

Cardiac failure+1

Recruiting

Study of Zenagamtide (NNC0487-0111) versus placebo in patients with heart failure with preserved or mildly reduced ejection fraction and obesity

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Zenagamtide
  • Sponsor:Novo Nordisk A/S

Dermatitis atopic

Recruiting

Phase 2b Randomized Double‑Blind Study of Oral PF‑08049820 in Adults with Moderate to Severe Atopic Dermatitis

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years
  • Substances:PF-08049820
  • Sponsor:Pfizer Inc.

Obesity+1

Recruiting

A study to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight and type 2 diabetes

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Obesity+2

Recruiting

Study of the efficacy and safety of Eloralintide in adults with knee osteoarthritis and overweight or obesity

Investigational
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:LY3841136 sodium
  • Sponsor:Eli Lilly & Co.

Ovarian epithelial cancer

Recruiting

Comparing AZD5335 with mirvetuximab soravtansine or a drug combination in patients with platinum-resistant ovarian cancer

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:AZD5335
  • Sponsor:AstraZeneca AB

Other cities in Czechia

The busiest research cities in the country

All 150 cities in Czechia

Clinical research in Novy Jicin

What the registry says about research in the country

01 Oncology Research

Multiple clinical trials focusing on various types of cancer, including non-small cell lung cancer, breast cancer, and prostate cancer. Studies are evaluating novel combination therapies and treatment approaches for advanced stages of disease.

  • Metastatic breast cancer treatments
  • Lung cancer therapies
  • Prostate cancer interventions

Emphasis on targeted therapies and immunotherapy combinations for improved patient outcomes.

02 Dermatology Studies

Comprehensive research into skin conditions, particularly plaque psoriasis and atopic dermatitis. Trials are investigating long-term safety and efficacy of new therapeutic agents.

  • Moderate to severe psoriasis treatments
  • Atopic dermatitis management
  • Long-term safety evaluations

Focus on developing sustainable treatment options for chronic skin conditions.

03 Specialty Medicine

Diverse research portfolio including studies in nephrology, gastroenterology, and rheumatology. Trials examining innovative treatments for conditions such as IgA nephropathy and short bowel syndrome.

  • Kidney disease treatments
  • Gastrointestinal disorders
  • Osteoarthritis interventions

Investigating targeted therapies for complex medical conditions.

Back to CzechiaAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.